Close

Lenti-DLL3 VHH(X3XH162) h(28BBζ) CAR-VP (XS-0323-LX1269)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The ready-to-use lentiviral particles of Lenti-DLL3 VHH(X3XH162) h(28BBζ) CAR-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a EF-1a promotor. The target gene of VHH (X3XH162)-CD28-41BB-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specific Inquiry

  • Size:
  • Marker:
  • Titer:
  Add to Cart

Specifications

  • Target
  • DLL3
  • Expression Cassette
  • VHH-CD28-41BB-CD3ζ
  • Promotor
  • EF1A
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Primary or metastatic cancer expressing DLL3

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Lenti-DLL3 VHH(X3XH162) h(CD28-41BB-CD3ζ) CAR, Viral Particle (XS-0323-LX1269). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.